A Study of HDM2024 in Participants With Advanced Solid Tumors

The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are: * Is the drug safe and tolerable ? * Does the drug exhibit antitumor activity ? Participants will receive the study drug once every three weeks, and imaging-based efficacy assessments will be performed every six weeks.

NCT Number	NCT07539285
Lead Sponsor	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions	Advanced Solid Tumors
Enrollment	63 participants
Start Date	2026-04-10
Primary Completion	2027-04-15 (estimated)
Study Completion	2028-12-28 (estimated)
Updated on ClinicalTrials.gov	2026-04-20